Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to 8 new employees to purchase an aggregate of 223,500 shares, effective January 2, 2026.
The awards were approved under Olema's 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.28 per share — equal to the last reported Nasdaq sale price on January 2, 2026. Awards are subject to plan terms and continuous employment for vesting.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OLMA declined 0.71%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While OLMA showed a 1.12% gain pre-announcement, key biotech peers like ARVN, SAGE, BCAX, ORKA, and VSTM all showed negative price changes today, indicating stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Inducement grants | Neutral | +0.4% | Inducement stock options for two new employees under 2022 Inducement Plan. |
| Nov 21 | Conference participation | Positive | +8.1% | Participation in 8th Annual Evercore Healthcare Conference fireside chat. |
| Nov 20 | Public offering close | Neutral | +13.3% | Closing of $218.5M underwritten public offering of common stock. |
| Nov 19 | Offering pricing | Neutral | -3.5% | Pricing of $190.0M public offering of common stock at $19.00. |
| Nov 18 | Offering announcement | Neutral | +136.4% | Announcement of proposed common stock and pre-funded warrant offering. |
Recent news flow spans financing, conferences, and similar inducement grants, with generally positive price reactions to financing announcements and minimal reaction to prior inducement grants.
Over the last few months, OLMA issued several equity offerings and corporate updates. In November 2025, it announced and priced public offerings of common stock, with gross proceeds around $190.0M–$218.5M, followed by conference participation and an earlier inducement grant on December 1, 2025 for 65,000 shares. Clinical and financial filings in Q3 2025 highlighted advancing breast cancer programs and significant cash resources. Today’s inducement grant under Nasdaq Listing Rule 5635(c)(4) continues the pattern of using equity-based compensation for new hires.
Market Pulse Summary
This announcement details inducement stock options for 8 new employees covering 223,500 shares at an exercise price of $25.28, vesting over four years with a 10-year term, under the 2022 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4). It highlights continued team expansion rather than changes to clinical, commercial, or financial guidance. Investors may watch future filings and news for updates on trial progress, capital structure, and additional equity-based awards.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
exercise price financial
AI-generated analysis. Not financial advice.
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 8 new employees to purchase an aggregate of 223,500 shares of the Company's common stock, effective as of January 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What did Olema (OLMA) announce on January 5, 2026 regarding stock grants?
What is the exercise price and term of the OLMA inducement options granted January 2, 2026?
How do the Olema (OLMA) inducement stock options vest?
Under what plan and Nasdaq rule were the OLMA inducement awards granted?
Will OLMA disclose additional terms or conditions for the January 2026 inducement options?
